| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-04-11 | Auspherix (Australia) Auspherix Limited (UK) | resignation |
Infectious diseases | Resignation | ||
| 2016-04-11 | Diamyd Medical (Sweden) | nomination |
Autoimmune diseases - Metabolic diseases | Nomination | ||
| 2016-04-11 | Seventure Partners (France) | nomination |
Nomination | |||
| 2016-04-11 | GE Healthcare (USA - WI) Mayo Clinic (USA - Mn) Vitruvian Networks (USA - CA) | advanced software systems and manufacturing services to accelerate access to cell and gene therapies | collaboration | Technology - Services | Establishment of a new subsidiary in the US | |
| 2016-04-07 | Juno Therapeutics (USA - WA) WuXi AppTec (China) | JW Biotechnology | establishment of a new company in China |
Cancer - Oncology - Technology - Services | Joint-venture agreement | |
| 2016-04-07 | Kiadis Pharma (The Netherlands) | nomination |
Cancer - Oncology - Hematological diseases | Nomination | ||
| 2016-04-07 | Asymptote (UK) Asymptote (UK) | novel point-of-care thawing system for cell-based therapies | licensing | Technology - Services | Licensing agreement | |
| 2016-04-06 | Allergan (Ireland) Heptares Therapeutics (UK), subsidiary of Sosei Group (Japan) | subtype-selective muscarinic receptor agonists | Alzheimer's disease and other neurological diseases | R&D collaboration licensing |
Neurodegenerative diseases - Neurological diseases | R&D agreement |
| 2016-04-06 | Janssen Biotech, a J&J company (USA - NJ) Tesaro (USA - MA) | niraparib | prostate cancer | collaboration licensing |
Cancer - Oncology | Licensing agreement |
| 2016-04-05 | Dassault Systèmes (France) Ipsen (France) | 3DEXPERIENCE platform | collaboration |
Technology - Services | Collaboration agreement | |
| 2016-04-05 | AstraZeneca (UK) Regeneron Pharmaceuticals (USA - NY) | pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibody-drug conjugate | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-04-05 | Intarcia Therapeutics (USA - CA) | nomination |
Metabolic diseases | Nomination | ||
| 2016-04-04 | Intrexon (USA - MD) White Rock Capital Partners | Intrexon T1D Partners | type 1 diabetes | joint-venture |
Autoimmune diseases - Metabolic diseases | Joint-venture agreement |
| 2016-04-04 | Tiziana Life Sciences (UK) | nomination |
Cancer - Oncology - Immunological diseases | Nomination | ||
| 2016-04-04 | Acucela (USA - MA) The University of Manchester (UK) | human rhodopsin based optogenetic gene therapy | retinal degenerative diseases including retinitis pigmentosa . | licensing |
Ophtalmological diseases - Genetic diseases - Rare diseases | Licensing agreement |
| 2016-04-04 | AOP Orphan Pharmaceuticals (Austria) | nomination |
Rare diseases | Nomination | ||
| 2016-04-04 | Valera, a Moderna Therapeutics'venture (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2016-04-04 | Astex Pharmaceuticals (UK) AstraZeneca (UK) GSK (UK) Heptares Therapeutics (UK), a subsidiary of Sosei Group (Japan) UCB (Belgium) the Medical Research Council Laboratory of Molecular Biology (MRC-LMB) (UK) the University of Cambridge’s Nanoscience Centre (UK) FEI (USA - OR) | Cambridge Pharmaceutical Cryo-EM Consortium | collaboration |
Technology - Services | Collaboration agreement | |
| 2016-04-04 | Portola Pharmaceuticals (USA - CA) Daiichi Sankyo (Japon) | andexanet alfa and edoxaban | reversion of the anticoagulant activity of edoxaban | clinical research | Cardiovascular diseases - Hematologic diseases | Clinical research agreement |
| 2016-04-01 | PEP Therapy (France) Conectus Alsace (France) | therapeutic peptide based on the CP&IP (Cell Penetrating & Interfering Peptides) platform | type 2 diabetes | R&D |
Metabolic diseases | R&D agreement |
